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Abstract
Background: Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and is also
associated with autism spectrum disorders. Previous studies implicated BKCa channels in the neuropathogenesis
of FXS, but the main question was whether pharmacological BKCa stimulation would be able to rescue FXS
neurobehavioral phenotypes.
Methods and results: We used a selective BKCa channel opener molecule (BMS-204352) to address this issue in
Fmr1 KO mice, modeling the FXS pathophysiology. In vitro, acute BMS-204352 treatment (10 μM) restored the
abnormal dendritic spine phenotype. In vivo, a single injection of BMS-204352 (2 mg/kg) rescued the hippocampal
glutamate homeostasis and the behavioral phenotype. Indeed, disturbances in social recognition and interaction,
non-social anxiety, and spatial memory were corrected by BMS-204352 in Fmr1 KO mice.
Conclusion: These results demonstrate that the BKCa channel is a new therapeutic target for FXS. We show that
BMS-204352 rescues a broad spectrum of behavioral impairments (social, emotional and cognitive) in an animal
model of FXS. This pharmacological molecule might open new ways for FXS therapy.
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Background
Fragile X Syndrome (FXS) is the most common cause of
inherited mental deficiency and is associated with autistic
features [1]. FXS is caused by a CGG triplet expansion
in the FMR1 gene resulting in the absence of its coding
protein, Fragile X Mental Retardation Protein (FMRP).
This mRNA-binding protein regulates both localization
and translation of specific mRNAs in synaptic regions
[2], but also controls synaptic membrane proteins activity
through a translation-independent pathway [3]. As a
consequence of this synaptic disturbance, a preponderance
of long, thin and ’tortuous” dendritic spines in cortex is
observed in FXS patients brain [4]. Fmr1 knock-out (KO)
mouse [5], a murine model of human FXS, presents both
dendritic spines maturation abnormalities [6] and many
behavioral characteristics similar to human FXS, including
altered social interaction, occurrence of repetitive behav-
iors, hyperactivity and cognitive dysfunction [7,8].
In the last decade, a better understanding of the FXS
pathophysiology allowed to develop chemical therapeutics
targeting specific synaptic components. Numerous studies
have revealed that in the absence of FMRP, signaling
through group 1 metabotropic glutamate receptors (mGluR
1/5) is disturbed. This dysfunction might underlie either
the observed exaggerated synaptic long-term-depression or
the insensibility of mGluR 1/5-mediated neuronal/synaptic
protein synthesis stimulation [9]. Based on “other active
mGluR 1/5 functions”, various selective molecules were
tested in vitro on primary neuron cell cultures and in vivo
on several behavioral defects in both Fmr1 KO mice
and FXS patients [10-12]. Although promising results
were obtained, none of the tested therapeutic agents
demonstrated a full effect on FXS behavioral, cognitive
and molecular abnormalities. These reports prompt the
interest of developing novel therapeutic targets.
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Recent studies have demonstrated the implication of
potassium channels in FXS pathology [13]. Among them,
large-conductance Ca2+-activated K+ channels (BKCa
channels, also known as BK or Maxi-K channels), activated
by membrane depolarization and increased intracellular
Ca2+ concentration, are of particular interest because
of their control of Ca2+ concentration in neurons and
regulation of neurotransmitter release such as glutamate
[14,15]. Functional BKCa channels are assembled as
hetero-octamers of four α- subunits (KCNMA1 protein)
and four auxiliary β-subunits, where the β-subunit is a
tissue specific regulatory unit [16].
Several data provide convincing evidence that this
channel is closely linked to behavioral and cognitive dis-
orders. Our physical mapping of balanced chromosomal
aberrations revealed a KCNMA1 gene disruption in a
subject with autism and intellectual deficiency. This gene
haploinsufficiency induced a functional defect of BKCa
channels that might contribute to neurological symptoms
[17]. In addition, a mutation in the CRBN gene, an
upstream regulator of BKCa channel, has been also
associated with autosomal recessive non-syndromic mental
retardation [18]. Behavior analysis obtained in mouse in
which Kcnma1 gene was deleted, showed a critical role for
the BK channels in mechanisms underlying associative
learning [19]. The hypothesis concerning BKCa involve-
ment in FXS neuropathology was first proposed by Liao
et al. [20]. In primary neuron cultures from Fmr1 KO
embryos, the authors observed a decreased expression
of KCNMA1 protein. This defect suggested that some
component of autistic and cognitive disorders seen in
FXS might be, in part, due to BKCa channel activity
abnormalities. Recently, Deng et al. [3] have demon-
strated that BKCa current reduction in hippocampal
slices results from an FMRP translation-independent
effect. In hippocampal pyramidal neurons, and probably
in cortical neurons, FMRP regulates action potential dur-
ation, neurotransmitter release and short-term plasticity
through presynaptic BKCa channels. Based on all these
data, we propose BKCa channel as a new pharmacological
target in FXS therapy.
For this purpose, we used the fluoro-oxindole BMS-
204352 ((3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihy-
dro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one), as a
selective BKCa channel opener [16,17]. To investigate
the therapeutic potential of this molecule, its effect was
tested at first in vitro using a standardized primary
neuron culture protocol focused on the Fmr1 KO den-
dritic spines defects [6]. Based on promising in vitro re-
sults, we investigated its effect in in vivo conditions on
Fmr1 KO mice behavioral impairments as well as on
metabolites homeostasis at hippocampus level [21]. In
accordance with the main human clinical manifesta-
tions described in DSM-5 (Diagnostic and Statistical
Manual of Mental Disorders), our behavior investigations
concerned social/cognitive skills.
Methods
For a full methodological description, see the supplemen-
tary content that accompanies the online edition of this
article.
Animals
All experiments were done with adult (3–5 months old)
male Fmr1 KO mice and their wild-type (WT) littermates of
C57BL/6 J background [5]. Fmr1 mice were obtained from
the colony of the Aquitaine Institute for Cognitive and
Integrative Neuroscience in Bordeaux (France). Breeding
details were described in Additional file 1: supplementary
methods. The present experimental protocol received full
review and approval by the regional animal care and use
committee (CREEA) prior to conducting the experiments.
All possible efforts were made to reduce the number of
animals studied and to avoid their suffering.
Neuronal cell cultures and BMS-204352 treatment
Primary neuron cultures were prepared from male WT and
Fmr1 KO mice at embryonic day 15 (E15) as previously
described [22]. Neurons were DiI-labeled and dendritic
spine maturation were analysed using a protocol adapted
from [6]. Experiments and analysis were done as blind to
the genotype.
Behavioral assays
The experiments were conducted in two laboratories: The
Experimental and Molecular Immunology and Neuroge-
netics laboratory in Orléans, France (Laboratory A), and
The Aquitaine Institute for Cognitive and Integrative
Neuroscience in Bordeaux, France (Laboratory B). Mice
were bred and maintained in the two laboratories fol-
lowing identical procedures.
In order to assess the social, cognitive and emotional
components, we performed a direct social interaction test,
the three-chamber test, the Y maze, and the elevated plus
maze. The first two behavioral tests, i.e., the direct social
interaction test and the three-chamber test for sociability
and social recognition were conducted in parallel in both
laboratories. This experimental strategy was adopted in
order to assess the robustness and replicability of the
results obtained. The last two tests, i.e., the Y maze for
spontaneous alternation and the elevated plus maze
were carried out in Laboratory B and Laboratory A,
respectively. In order to minimize the number of animals
studied, the same mice were used during the first three
behavioral tests. Experiments and analysis were done as
blind to the genotype.
All behavioral tests are described in Additional file 1:
(Methods and Supplementary Results).
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Drug administration
The effective dose of BMS-204352 was chosen based on
previously published data [23,24]. BMS-204352 (2 mg/kg)
diluted in the vehicle solution (DMSO 1/80; Tween 80 1/
80; 0.9% NaCl) was administered by a 10 ml/kg single
intraperitoneal (i.p) injection. Behavioral tests were per-
formed at the maximal BMS-204352 brain concentration,
i.e., 30 min after injection (Details appear in Additional
file 1: Methods and Supplementary Results obtained by
LC-MS/MS method, Additional file 1: Figure S1).
Magnetic Resonance Spectroscopy (MRS)
MRS was realized as described previously with slight
modifications [25] in order to quantify brain metabolites:
glutamate, myo-inositol, N-Acetyl-Aspartate, taurine and
lactate. Ten Fmr1 KO and ten WT mice, which were not
used in the behavioral tests, were included in the study.
Metabolites concentrations are represented in arbitrary unit
(AU), after normalization by Creatine/Phosphocreatine.
Method is described in Additional file 1.
Statistical analysis
For behavioral tests, data were analysed using three-way
ANOVA with genotype, treatment, and laboratory as main
factors for the three compartment and social interaction
tests, and two-way ANOVA with genotype and treatment
for the Y maze and elevated plus maze. Within-subject
factors (e.g., contact area) were included when appropri-
ate. Fisher PLSD’s post-hoc comparisons were used when
a statistically significant main effect or interaction was
detected (p < 0.05). For in vitro analyses, data were
analysed using two-way ANOVA with genotype and
treatment as main effects followed by Fisher PLSD’s
post-hoc comparisons. All statistical analyses were done
using Statistica 8 (StatSoft). For MRS, metabolites con-
centrations obtained in WT or Fmr1 KO mice were
compared using t-test or Mann–Whitney tests when non-
parametric analysis was required. Treatment efficiency
was evaluated by Wilcoxon tests.
Results
BMS-204352 reverses dendritic spine abnormal phenotype
Increased dendritic spine density and length was reported
in post-mortem analysis of FXS patients brain tissues [4]
and observed in Fmr1 KO mice in vivo [26] as well as
in vitro on primary neuron cultures [6]. Vehicle-treated
Fmr1 KO neurons showed a significantly higher filopodia
length (3.00 ± 0.15 μm vs 1.67 ± 0.2 μm, p < 0.0001) and
density (0.93 ± 0.11 nbr/10 μm vs 0.15 ± 0.04 nbr/
10 μm, p < 0.001) compared to vehicle-treated WT neurons
(Figure 1). Acute treatment (4 hrs) with BMS-204352
10 μM corrected the Fmr1 KO dendritic spine phenotype,
whereas, BMS-204352 5 μM had no significant effect
on Fmr1 KO neurons. Indeed, BMS-204352 10 μM
significantly reduced filopodia length (1.72 ± 0.12 μm,
p < 0.01) and density (0.21 ± 0.04 nbr/10 μm, p < 0.01)
of Fmr1 KO neurons. In WT neurons, BMS-204352
(5 μM or 10 μM) acute treatment had no significant
effect on the dendritic spine length or density.
BMS-204352 reverses impaired social behavioral
phenotype
Impairments in social interactions are core symptoms
in FXS patients [1]. The assessment of Fmr1 KO direct
social interaction and BMS-204352 effect was conducted
in two different laboratories (Laboratories A and B). A
non-significant effect of laboratory [F(1,77) = 1.12, NS]
and of its interactions with genotype [F(1,77) = 0.62,
NS], treatment [F(1,77) = 0.39, NS] and both factors
[F(1,77) < 1, NS] was observed. On the other side, a
significant interaction of genotype and treatment was
noticed [F(1,77) = 10.66, p < 0.01]: regardless the labo-
ratory, vehicle-treated Fmr1 KO showed significantly
reduced social interactions with a stimulus female
mouse compared to vehicle-treated WTanimals [post-hoc,
p < 0.01], and this reduced social investigation was
corrected by BMS-204352 [post-hoc, p < 0.01], while a
tendency to a negative effect of the treatment was
observed in WT [post-hoc, p = 0.06] (Figure 2a). Indeed, a
single BMS-204352 2 mg/kg injection in Fmr1 KO mice
was able to correct their deficits in social interactions,
making them indistinguishable from WT mice. These
results were confirmed in both laboratories, despite the
obvious differences in environmental factors, i.e., exper-
imenters (Additional file 1: Figure S2a-b).
To go further, we performed a second test in order to
assay sociability, the three-chamber test. In the habituation
phase (trial 1), all mice did not show a preference for
any compartment or contact area in both laboratories
(Additional file 1: Figure S2c-d). No difference between
genotypes and treatments was observed for locomotor
activity (Additional file 1: Figure S2g).
In trial 2, all mice preferentially explored the contact
area containing the stimulus mouse compared to the
one with the object, [main effect of contact area: F
(1,112) = 54.11, p < 0.0001; Figure 2c], without difference
between genotypes and treatments. A main effect of
laboratories was observed [F(1,112) = 6.71, p < 0.05]
since mice from Laboratory B spent more time in both
contact areas, without interaction between genotype and
treatments (Additional file 1: Figure S2e). These results
confirmed the lack of deficits in sociability previously de-
scribed in Fmr1 KO mice in this test [8,27-29]. Locomotor
activity was similar in Fmr1 KO and WT mice [main effect of
genotype: F(1,112) = 2.25, NS ; Additional file 1: Figure S2h].
In trial 3, the social recognition trial, WT mice pre-
ferred to spent time in contact with the novel compared
to the familiar mouse [main effect of contact area:
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F(1,112) = 8.81, p < 0.01], but this effect was modulated
by both genotype and treatment [interaction genotype ×
treatment × contact area: F(1,112) = 10.02, p < 0.01].
Indeed, separate analyses in each group revealed that
vehicle-treated WT mice showed a marked preference
for social novelty, while this was absent in vehicle-treated
Fmr1 KO mice [interaction genotype x contact area:
F(1,74) = 7.31, p < 0.01]. This deficit in social recognition
was abolished by BMS-204352 treatment in Fmr1 KO
mice [interaction contact area x treatment: F(1,65) = 4.74,
p < 0.05], as shown by the heat map illustration (Figure 2b),
although a tendency to a negative effect was observed in
WT mice [interaction contact area × treatment: F(1,51) =
3.27, p = 0.08; Figure 2d]. This negative effect in the
WT mice was the consequence of an increase time
spent in contact to familiar mouse versus a decrease time
spent in contact to novel mouse (Figure 2d). All these
effects were equivalently observed in both laboratories
[all interactions with laboratory, NS; data not shown].
As in trial 2, a main effect of laboratory was ob-
served [F(1,112) = 6.11, p < 0.05], without any conse-
quences on the area preference or the differences
between genotypes and treatments (Additional file 1:
Figure S2f ).
In this trial, locomotor activity was significantly higher
in Fmr1 KO mice compared to WT mice [main effect
of genotype: F(1,112) = 5.76, p < 0.05], and this effect
was not abolished by BMS-204352 treatment [interaction
genotype x treatment: F(1,112) < 1, NS; Additional file 1:
Figure S2i].
BMS-204352 reverses impaired emotional behavioral
phenotype
The emotional component was evaluated by the elevated
plus maze. As described in the literature [29,30] Fmr1
KO mice presented reduced non-social anxiety in this
Figure 1 BMS-204352 at 10 μM rescues dendrite spines maturation in Fmr1 KO neurons cultures. (a) Representative pictures of neuron
dendrites in different culture conditions with BMS-204352 (5 or 10 μM) or with only its vehicle (DMSO 0.1%). Red arrows indicate filopodia. Scale
bar = 10 μm (b) Filopodia length (μm) and (c) density (nbr/10 μm) were investigated in each condition. A two-way ANOVA revealed that vehicle-treated
Fmr1 KO neurons showed a significantly higher filopodia length and density compared to vehicle-treated WT neurons. Acute treatment (4 hrs) with
BMS-204352 10 μM corrected the Fmr1 KO dendritic spine phenotype, whereas, BMS-204352 5 μM had no significant effect on Fmr1 KO neurons.
NS, not significant; ***p < 0.001 for genotype comparison; #p < 0.05 for treatment comparison; n = 60 neurons (from 10 mice) in all groups. Data
represent mean ± s.e.m.
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maze. Anxious mice naturally avoid open spaces and
spend more time in closed arms, and less anxious mice
spend more time exploring the open arms. The percent-
age of time spent in open arms is usually used as anxiety
measure. The analysis demonstrated that Fmr1 KO mice
presented an elevated percentage compared to WT mice
[F(1,77) = 8.51, p < 0.001; Figure 3a]. Also, they presented
higher number of entries and time spent in open arms
than WT mice [number of entries: F(1,77) = 4.04, p < 0.05;
time spent: F(1,77) = 9.38, p < 0.01] (Additional file 1:
Figure S3c and S3a, respectively), but the treatment had
no effect [F(1,77) < 1, NS]. On the other hand, the time
spent in closed arms did not differ between groups
[F(1,77) < 1, NS; Additional file 1: Figure S3b]. Also, the
amount of time spent in the extremities of the open arms
has been established as a good index of anxiety [31-34].
Fmr1 KO mice spent more time in the extremity of
open arms [genotype effect: F(1,77) = 5.31, p < 0.05]
and this was corrected by BMS-204352 that also in-
creased non-social anxiety in WT mice [treatment
effect: F(1,77) = 4.06, p < 0.05; Figure 3b].
For the distance moved, Fmr1 KO mice were hyper-
active compared to WT mice, and this genotype difference
disappeared following BMS-204352 treatment [interaction
genotype × treatment: F(1,77) = 8.08, p < 0.01]. Indeed,
BMS-204352 significantly increased locomotion in WT
mice, while tended to decrease it in Fmr1 KO mice
(Additional file 1: Figure S3d).
Figure 2 BMS-204352 effects on Social behaviors. Mice were administered with BMS-204352 2 mg/kg or vehicle (veh) and subjected to social
behavioral tests 30 min after the injection. (a) Histograms represent time spent in affiliative behaviors obtained in two laboratories. A three-way
ANOVA indicated a non-significant effect of laboratory, but a significant interaction between genotype and treatment. Vehicle-treated Fmr1 KO
mice spent less time in affiliative behavior compared to WT, but BMS-204352 injection restored a normal social investigation. (n: WT-veh = 27;
WT-2 mg/kg = 16; KO-veh = 25; KO-2 mg/kg = 17). NS, not significant; **p < 0.05 compared to the corresponding WT; ##p < 0.05 compared the
corresponding treated group. (b) Illustration of BMS-204352 effect on the three-chamber test by a pseudo-colored heat map representing time
spent at each positions related to the social preference trial (fam: familiar mouse, novel: novel mouse). (c) Preference for a conspecific versus an
object in the three-chamber test was measured by the time spent in the contact area when a stranger mouse and an object were accessible.
Repeat-measures ANOVA indicated that vehicle-treated KO mice like WT shown a preference for the mouse versus the object, and that BMS-204352
treatment had no effect. (d) Preference for a novel versus a familiar mouse, was measured by the time spent in the contact area when a stranger and a
familiar mouse were accessible. In vehicle-treated groups a preference for the novel mouse was only observed in WT. This preference was rescued by
BMS-204352 treatment in Fmr1 KO mice. (n: WT-veh = 34; WT-2 mg/kg = 19; KO-veh = 42; KO-2 mg/kg = 25). NS, not significant; *p < 0.05, **p < 0.01
and ***p < 0.001 (object versus mouse, familiar versus novel mouse). Data represent mean ± s.e.m.
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BMS-204532 reverses impaired cognitive behavioral
phenotype
The cognitive component was investigated through a
hippocampus-dependent test, the Y maze for spontaneous
alternation [35]. A two-trial memory task in a Y-maze,
based on a free-choice exploration paradigm, has been
previously developed to study recognition processes [36,37].
Fmr1 KO mice showed a deficit in spontaneous alternation
and it was abolished by BMS-204352 treatment. The ana-
lysis of the percent novelty preference index demonstrated
that spontaneous alternation was reduced in vehicle-treated
Fmr1 KO mice versus vehicle-treated WT mice, while
returned to WT levels in BMS-treated Fmr1 KO group,
[interaction genotype x treatment: F(1,23) = 4.78, p < 0.05;
post-hoc: p = 0.048; Figure 3c]. Moreover, the distance
moved during the test did not differ between experimental
groups: there was no effect of genotype or treatment
[F(1,23) = 2.52, p = 0.13; F(1,23) = 1.17, p = 0.29 respect-
ively] (Additional file 1: Figure S3e).
BMS-204352 impacts brain metabolites level in vivo
It has been suggested that glutamate signaling cascade in
the absence of FRMP played a causal role in the behavioral
phenotype of Fmr1 KO mice [38]. In vivo effects of 2 mg/
kg BMS-204352 treatment on glutamate concentration
were studied by MRS experiments on the hippocampus
structure. Vehicle-treated Fmr1 KO mice presented a
significant lower (p = 0.009) hippocampal glutamate
concentration compared to vehicle-treated WT mice.
Injection of 2 mg/kg BMS-204352 in Fmr1 KO mice
led to a significant (p = 0.043) increase of glutamate
level (Figure 4a). Interestingly, this injection restored a
WT glutamate level since no difference was observed
between 2 mg/kg BMS-204352-treated Fmr1 KO and
vehicle-treated WT mice. An increased in glutamate
was also observed (p = 0.043) after BMS-204352 injection
in WT mice.
BMS-204352 single injection also restored the concen-
tration of myo-inositol. Indeed, myo-inositol level was
slightly higher (p = 0.053) with an important dispersion
in vehicle-treated Fmr1 KO mice compared to vehicle-
treated WT littermates (Figure 4b). In Fmr1 KO mice
BMS-204352 induced a significant decrease (p = 0.002)
in myo-inositol concentration, reaching a concentration
similar to vehicle-treated WT level. A similar decrease
(p = 0.038) was observed after BMS-204352 treatment in
Figure 3 BMS-204352 effects on Emotionality and Spatial memory. (a) Percentage of time spent in open arms time in the elevated plus
maze was calculated as the time in open arms/all arms x100. Analysis indicated a main effect of genotype, but no difference between genotypes
and treatments was observed. (b) Time spent in the extremity of open arms was also evaluated and showed that Fmr1 KO mice exhibited reduced
non-social anxiety in comparison to WT mice. This was corrected by BMS-204352 treatment that increased anxiety in both genotypes. *p < 0.05
(n: WT-veh = 32; WT-2 mg/kg = 7; KO-veh = 32; KO-2 mg/kg = 10). (c) Preference index for a novel arm in the Y-maze was determined by the time
spent in the novel arm/ time spent in all 3 arms. Fmr1 KO mice presented spatial memory impairments through their incapacity to distinguish between
novel and familiar arms. BMS-204352 treatment restored this cognitive defect to WT level. Significance was determined using two-way ANOVA with
post-hoc PLSD test. NS, not significant; *p < 0.05, vs. WT; #p < 0.05 vs. KO-veh (n: WT-veh = 7; WT-2 mg/kg = 6; KO-veh = 7; KO-2 mg/kg = 7). Data
represent mean ± s.e.m.
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WT mice. Vehicle-treated Fmr1 KO mice also presented
significant deregulation of Taurine, N-Acetyl-Aspartate
and Lactate metabolites (Additional file 1: Figure S4).
In those mice, BMS-204352 (2 mg/kg) treatment had a
significant effect on taurine and lactate concentration,
restoring a WT level.
Discussion
Currently, accumulated evidences highlight BKCa channel
as a potential therapeutic target for FXS. Indeed, in vitro
in the absence of FMRP, BKCa alpha subunit protein
(KCNMA1) expression is decreased both in primary
neuron cultures of Fmr1 KO mice [20] and lymphoblas-
toid cells derived from FXS patients (Additional file 1:
Figure S5). Moreover, Deng et al. [3] demonstrated that
BKCa currents were decreased in CA3 pyramidal neuron
of Fmr1 KO mice. Dysregulation of neurotransmitter
release and short-term plasticity, as a consequence of
these defects, should in turn contributed to the behavior
and cognitive deficits [3]. Therefore, we hypothesized that
enhancing BKCa channel activity could rescue FXS neuro-
behavioral phenotypes. To this end, we chose to test the
effects of fluoro-oxindole BMS-204352, a sensitive BKCa
channel opener [17,39], on the dendritic spines phenotype,
behavioral impairments and the cellular hippocampal
metabolism of the murine FXS model, the Fmr1 KO mice.
At first, before conducting our in vivo experiments,
we decided to evaluate BMS-204352 in vitro effects on
dendritic spine morphology in primary neuron cell cultures
from Fmr1 KO embryos [4,6,40-42]. We showed that an
acute treatment with BMS-204352 was able to restore the
dendritic defects, typically observed in Fmr1 neurons,
to a regular level. This finding suggests that BKCa channel,
which was previously defined as a determinant of presynap-
tic activity [15], should contribute to synaptogenesis. Hypo-
thetically, these neuromorphological changes observed
should directly link to local modulation of potassium flux,
induced by an open conformational state of BK channel, as
other potassium channels have been demonstrated to be
closely associated with filopodia growth, dendritic develop-
ment and/or neuronal differentiation [43,44]. However, the
link between local potassium ionic flux and the cellular
pathway involved in dendritic maturation is worth being
further explored.
Figure 4 BMS-204352 effects on glutamate and myo-inositol brain level. Mice (3–5 months) were administered with BMS-204352 at 2 mg/kg
or vehicle (veh) and subjected to MRS test 30 min after the injection. Box plots (shown as the minimum, 1st quartile, mean, median, 2nd quartile and
maximum values) represent (a) glutamate and (b) myo-inositol concentrations in arbitrary unit (AU), after normalization by Creatine/Phosphocreatine,
in vehicle or BMS-204352-treated-WT and Fmr1 KO mice. Glutamate level was significantly decreased in Fmr1 KO mice compared to WT, whereas
myo-inositol concentration was increased. Furthermore, a single injection of BMS-204352 rescued a WT like metabolites concentration. Significance
between WT and KO was determined using Mann–Whitney test and impact of treatment was determined by Wilcoxon test. NS, not significant; **p < 0.01
for genotype comparison; #p < 0.05 for treatment comparison (n: WT-veh = 10; WT-2 mg/kg = 10; KO-veh = 10; KO-2 mg/kg = 10).
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The in vitro beneficial effects of several molecules
on dendritic spine maturation of Fmr1 KO mice were
correlated with in vivo endophenotype observations
[6,45,46]. BMS-204352 effects were investigated in vivo
after intraperitoneal injection at 2 mg/kg [23,24]. As previ-
ously described, adult Fmr1 KO mice exhibited social
behavioral impairments in a direct social interaction test
as demonstrated by lower level of affiliative behaviors
[27,28,47]. After injection of BMS-204352 2 mg/kg,
affiliative behaviors in Fmr1 KO mice were significantly
increased to the WT level. To confirm and complete
the results obtained in the direct social interaction test,
we performed a three-chamber test, which showed social
impairments in Fmr1 KO mice demonstrated by their
inability to distinguish a novel mouse from a familiar
one, as previously described [27,28,47]. The observed
effect in sociability components is very robust, as these
tests were performed by different experimenter, in two
different laboratories with two distinct cohorts of mice.
Interestingly, during trial 2 (sociability trial), Fmr1 KO
mice and their WT littermates exhibited the same level
of interest in the stimulus mouse compared to a non-social
stimulus [27,28,47]. During this trial only olfactory and
visual modalities come into play, and only the experi-
mental mouse can initiate social contact. The reduced
level of interactions of Fmr1 KO mice during the direct
social interaction test, is therefore most probably due
to social anxiety induced by the direct contact with the
stimulus mouse. In contrast, Fmr1 KO mice exhibited
reduced non-social anxiety compared to WT mice in
the elevated plus maze [29]. Reduced non-social anxiety
was rescued to normal levels after BMS-204352 treatment
based on the time spent in the extremity of open arms.
An acute treatment with BMS-204352 was therefore able
to rescue the social deficits of Fmr1 KO mice by increas-
ing affiliative behaviors, decreasing social anxiety and
enhancing social recognition. Our results are extended
by spatial recognition test using Y-maze test. Fmr1 KO
mice presented spatial memory impairments through
their incapacity to distinguish novel arm from familiar
arms. This is in agreement with several studies which use
different maze [6,8,48]. BMS-204352 treatment restored
this cognitive impairment to WT level.
Therefore, we demonstrated that an acute BMS-204352
treatment at 2 mg/kg restored a normal phenotype in
social, cognitive and emotional components by improving
sociability, social and spatial recognition, and social/non-
social anxiety.
Currently, distinct therapeutic targets are under inves-
tigations involving Fmr1 KO mice. Many studies provide
compelling evidence for several potential efficient pharma-
cological products. However, the comparison between
those studies and ours was limited because they involved
different mazes, molecules or strains. To our knowledge,
our study is the first investigation to evaluate the efficiency
of an acute treatment on the three main components of
adult Fmr1 knock-out mouse behavioral deficits: social,
emotional and cognitive. Moreover, long-term study will
provide additional data on phenotypic improvements
already observed with a single-dose treatment. Indeed,
positive behavioral effect due to BMS-20352 single
injection were no longer observed 180 minutes after the
injection (Additional file 1: Figure S6), likely due to the
short BMS-204352 half-life (Additional file 1: Figure S1).
Therefore, this long-term investigation will allow us to
explore further cognitive traits such as learning and
long-term memory, since Typlt et al. proposed a crucial
role of the BKCa channels in learning [19].
As suggested before, in the absence of FMRP, numerous
impairments of synaptic function were described with
direct consequences on signaling cascades and cellular
metabolism [3,49,50]. Moreover, presynaptic location of
BKCa channels might provide a homeostatic mechanism
for regulating synaptic transmission [3,15]. Accordingly,
we investigated BMS-204352 treatment effects on meta-
bolic profile of Fmr1 KO mice hippocampus with MRS
method. The advantage of this non-invasive method was
to obtain a metabolomic profile of a brain area in anaes-
thetized animals, unlike to other methods which required
dissected tissues. By this MRS method, we showed that
glutamate concentration was significantly reduced in our
adult Fmr1 KO mice compared to WT mice. A similar
glutamate decrease was also described by 1H HR-MAS
NMR spectroscopy on cortex of 12 days of age Fmr1
KO FVB mice, suggesting that excitatory input appears
compromised [50,51]. Our result support the hypothesis
previously published that glutamatergic function disturb-
ance might contribute to FXS phenotypes in mice [3,49,50].
In our conditions, this glutamate reduction was rescued by
a single injection of BMS-204352 at 2 mg/kg. Consistently
with our behavioral experiments, BKCa channel opener
should be a valuable tool to regulate glutamate neuro-
transmission and metabolism.
In addition, myo-inositol, mainly presents in astro-
cytes [52], was found deregulated in Fmr1 KO mice.
Myo-inositol concentration is altered in brain disorders
such as Alzheimer’s disease and often, elevation of myo-
inositol level reflects an astrocytic activation [53]. In our
study, Fmr1 KO mice also presented an elevated myo-
inositol concentration suggesting an activation of astro-
cytes. This was consistent with glial fibrillary acidic
protein (GFAP) and its mRNA up-expressions previously
observed in several brain regions [51]. All of these data
are consistent with an astrocyte involvement in synaptic
defects observed in Fmr1 KO mice [54-56]. Interestingly,
BMS-204352 acute treatment decreased the myo-inositol
concentration to WT level, however molecular and cel-
lular pathways involved remained unclear. Based on
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these results, we suggest that BMS-204352 should be
able to treat functional alteration of the tripartite
synapse involved in the Fmr1 phenotype [55,56].
Conclusion
All these data reinforced evidences that BKCa pathway
has to be explored as a new interesting therapeutic target
for FXS patient. Therefore, our results suggested that
BKCa channel opener molecule (BMS-204352) constitutes
a promising potential medication for FXS patients correct-
ing a broad spectrum of behavioral impairments (social,
emotional and cognitive). BMS-204352 went up to phase
III trial for the treatment of acute ischemic stroke but
failed to show improvement against placebo. However
during trials no organ toxicity or adverse effects were
found [24]. This allows us to look forward with confidence
to clinical trials involving few FXS patients.
Additional file
Additional file 1: Additional Methods description and Results are
presented in Additional file 1.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
BH, SP, JP, AM, OP and SB conceived and designed the experiments; BH, SP,
AL and OP performed the behavioral experiments; SM and BH performed the
SRMN; AQ, AM, ND and OP performed the in vitro experiments; DC produced
deuterated molecule for kinetic assay; SL and LG performed molecule kinetic
assay; BH, SP and OP analyzed the data; BH, AM and OP wrote the manuscript;
SP, BL, ND, FL, WC, JP, AM, and SB coordinated and helped to draft the
manuscript. All authors read and approved the final manuscript.
Authors’ information
Betty Hebert and Susanna Pietropaolo are equal first contributors (co-first authors).
Olivier Perche and Sylvain Briault are equal contributors (co-final authors).
Acknowledgments
We would like to thank Mélanie Marcos for her excellent technical support
and Alexandre Herpin, Jerôme Larrigaldie and Ludovic Mercier for animal
breeding. We also thank Jean-Claude Beloeil and Valérie Quesniaux for their
continued support of the project. Research was supported in part by grants
from Fondation de France 015448, The FRAXA Research Foundation (USA),
FEDER Autism 35106, Fondation Lejeune, CNRS (Soutien au transfert 04388–02),
Région Centre, Regional Hospital of Orléans, the University of Orléans and
Project FP7 GENCODYS (n°241995, to FL). W.C. and S.P. were supported by
grants from the March of Dimes (12-FY05-1198), Conseil Régional d’Aquitaine,
CNRS, and the University of Bordeaux 1 to W.C.
Author details
1UMR7355, CNRS, Orléans, France. 2Experimental and Molecular Immunology
and Neurogenetics, University of Orléans, 3b rue de la Férollerie, 45071
Orléans, Cedex 2, France. 3The Aquitaine Institute for Cognitive and
Integrative Neuroscience, UMR 5287, CNRS, Talence, France. 4The Aquitaine
Institute for Cognitive and Integrative Neuroscience, University of Bordeaux,
Avenue des Facultés, 33405 Talence, France. 5Centre de Biophysique
Moléculaire, UPR4301, CNRS, University of Orléans, Rue Charles Sadron, 45071
Orléans, Cedex, France. 6Genetic department, Regional Hospital, 14 Avenue
de l’Hôpital, 45100 Orléans, France. 7UMR CNRS 6014 C.O.B.R.A., INSA of
Rouen, 1 rue Tesnière, 76821 Mont Saint Aignan, France. 8INSERM, U930,
Tours 37032, France. 9UMR Imagerie et cerveau, François-Rabelais University,
Tours 37000, France.
Received: 10 February 2014 Accepted: 21 July 2014
Published: 1 August 2014
References
1. Hagerman RJ: Advances in the treatment of fragile X syndrome. Pediatrics
2009, 123:378–390.
2. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF,
Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB: FMRP stalls
ribosomal translocation on mRNAs linked to synaptic function and
autism. Cell 2011, 146:247–261.
3. Deng PY, Rotman Z, Blundon JA, Cho Y, Cui J, Cavalli V, Zakharenko SS,
Klyachko VA: FMRP regulates neurotransmitter release and synaptic
information transmission by modulating action potential duration via BK
channels. Neuron 2013, 77:696–711.
4. Irwin SA, Galvez R, Greenough WT: Dendritic spine structural anomalies in
fragile-X mental retardation syndrome. Cereb Cortex 2000, 10:1038–1044.
5. Bakker CE, Verheij C, Willemsen R, Helm R, Oerlemans F, Vermey M: Fmr1
knockout mice: a model to study fragile X mental retardation. The
Dutch-Belgian Fragile X Consortium. Cell 1994, 78:23–33.
6. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM:
Minocycline promotes dendritic spine maturation and improves
behavioural performance in the fragile X mouse model. J Med Genet
2009, 46:94.
7. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE: Behavioral and
neuroanatomical characterization of the Fmr1 knockout mouse.
Hippocampus 2002, 12:39–46.
8. Pietropaolo S, Guilleminot A, Martin B, D’Amato FR, Crusio WE: Genetic-
background modulation of core and variable autistic-like symptoms in
Fmr1 knock-out mice. PLoS One 2011, 6:e17073.
9. Gross C, Berry-Kravis EM, Bassell GJ: Therapeutic strategies in fragile X
syndrome: dysregulated mGluR signaling and beyond.
Neuropsychopharmacology 2012, 37:178–195.
10. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP: Suppression of two major
fragile X syndrome mouse model phenotypes by the mGluR5 antagonist
MPEP. Neuropharmacology 2005, 49:1053–1066.
11. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS: Lithium
ameliorates altered glycogen synthase kinase-3 and behavior in a mouse
model of fragile X syndrome. Biochem Pharmacol 2010, 79:632–646.
12. Pacey LK, Tharmalingam S, Hampson DR: Subchronic administration and
combination metabotropic glutamate and GABAB receptor drug therapy
in fragile X syndrome. J Pharmacol Exp Ther 2011, 338:897–905.
13. Lee HY, Jan LY: Fragile X syndrome: mechanistic insights and therapeutic
avenues regarding the role of potassium channels. Curr Opin Neurobiol
2012, 22:887–894.
14. Latorre R, Brauchi S: Large conductance Ca2 + −activated K + (BK)
channel: activation by Ca2+ and voltage. Biol Res 2006, 39:385–401.
15. Salkoff L, Butler A, Ferreira G, Santi C, Wei A: High-conductance potassium
channels of the SLO family. Nat Rev Neurosci 2006, 7:921–931.
16. Nardi A, Olesen SP: BK channel modulators: a comprehensive overview.
Curr Med Chem 2008, 15:1126–1146.
17. Laumonnier F, Roger S, Guerin P, Molinari F, M’Rad R, Cahard D, Belhadj A,
Halayem M, Persico AM, Elia M, Romano V, Holbert S, Andres C, Chaabouni
H, Colleaux L, Constant J, Le Guennec JY, Briault S: Association of a
functional deficit of the BKCa channel, a synaptic regulator of neuronal
excitability, with autism and mental retardation. Am J Psychiatry 2006,
163:1622–1629.
18. Higgins JJ, Hao J, Kosofsky BE, Rajadhyaksha AM: Dysregulation of large-
conductance Ca2 + −activated K + channel expression in nonsyndromal
mental retardation due to a cereblon p.R419X mutation. Neurogenetics
2008, 9:219–223.
19. Typlt M, Mirkowski M, Azzopardi E, Ruettiger L, Ruth P, Schmid S: Mice with
deficient BK channel function show impaired prepulse inhibition and
spatial learning, but normal working and spatial reference memory. PLoS
One 2013, 8:e81270.
20. Liao L, Park SK, Xu T, Vanderklish P, Yates JR 3rd: Quantitative proteomic analysis
of primary neurons reveals diverse changes in synaptic protein content in
fmr1 knockout mice. Proc Natl Acad Sci U S A 2008, 105:15281–15286.
21. Briault S, Perche O: Compositions for the treatment of fragile X syndrome.
In Book Compositions for the Treatment of Fragile X Syndrome, Editor ed.
^eds. City: WO Patent 2/013/001/412; 2013.
Hébert et al. Orphanet Journal of Rare Diseases 2014, 9:124 Page 9 of 10
http://www.ojrd.com/content/9/1/124
22. Ethell IM, Irie F, Kalo MS, Couchman JR, Pasquale EB, Yamaguchi Y: EphB/
syndecan-2 signaling in dendritic spine morphogenesis. Neuron 2001,
31:1001–1013.
23. Gribkoff VK, Starrett JE Jr, Dworetzky SI: Maxi-K potassium channels: form,
function, and modulation of a class of endogenous regulators of
intracellular calcium. Neuroscientist 2001, 7:166–177.
24. Jensen BS: BMS-204352: a potassium channel opener developed for the
treatment of stroke. CNS Drug Rev 2002, 8:353–360.
25. Meme S, Calas AG, Montecot C, Richard O, Gautier H, Gefflaut T, Doan BT,
Meme W, Pichon J, Beloeil JC: MRI characterization of structural mouse
brain changes in response to chronic exposure to the glufosinate
ammonium herbicide. Toxicol Sci 2009, 111:321–330.
26. Galvez R, Greenough WT: Sequence of abnormal dendritic spine
development in primary somatosensory cortex of a mouse model
of the fragile X mental retardation syndrome. Am J Med Genet A 2005,
135:155–160.
27. McNaughton CH: Evidence for social anxiety and impaired social
cognition in a mouse model of fragile X syndrome. Behav Neurosci 2008,
122:293–300.
28. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL,
D’Ercole AJ, Crawley JN, Magnuson TR, Lauder JM: Social approach in
genetically engineered mouse lines relevant to autism. Genes Brain Behav
2009, 8:129–142.
29. Liu Z-H, Smith CB: Dissociation of social and nonsocial anxiety in a mouse
model of fragile X syndrome. Neurosci Lett 2009, 454:62–66.
30. Qin M, Xia Z, Huang T, Smith CB: Effects of chronic immobilization stress
on anxiety-like behavior and basolateral amygdala morphology in Fmr1
knockout mice. Neuroscience 2011, 194:282–290.
31. Cardenas F, Lamprea MR, Morato S: Vibrissal sense is not the main sensory
modality in rat exploratory behavior in the elevated plus-maze. Behav
Brain Res 2001, 122:169–174.
32. Estanislau C, Morato S: Behavior ontogeny in the elevated plus-maze:
prenatal stress effects. Int J Dev Neurosci 2006, 24:255–262.
33. Garcia AM, Martinez R, Brandao ML, Morato S: Effects of apomorphine on
rat behavior in the elevated plus-maze. Physiol Behav 2005, 85:440–447.
34. Martinez RC, Garcia AM, Lamprea MR, Morato S: Thermal stress decreases
general motor activity of rats in the elevated plus-maze but does not
alter aversion to the open arms. Behav Brain Res 2007, 182:135–139.
35. Dellu F, Contarino A, Simon H, Koob G, Gold L: Genetic differences in
response to novelty and spatial memory using a two-trial recognition
task in mice. Neurobiol Learn Mem 2000, 73:31–48.
36. Dellu F, Fauchey V, Moal ML, Simon H: Extension of a new two-trial
memory task in the rat: influence of environmental context on recognition
processes. Neurobiol Learn Mem 1997, 67:112–120.
37. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H: A two-trial memory
task with automated recording: study in young and aged rats. Brain Res
1992, 588:132–139.
38. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental
retardation. Trends Neurosci 2004, 27:370–377.
39. Gribkoff VK, Starrett JE, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA,
Frantz SW, Heman K, Hibbard JR, Huston K: Targeting acute ischemic
stroke with a calcium-sensitive opener of maxi-K potassium channels.
Nat Med 2001, 7:471–477.
40. Thomas CC, Combe CL, Dyar KA, Inglis FM: Modest alterations in patterns
of motor neuron dendrite morphology in the Fmr1 knockout mouse
model for fragile X. Int J Dev Neurosci 2008, 26:805–811.
41. Grossman AW, Aldridge GM, Lee KJ, Zeman MK, Jun CS, Azam HS, Arii T,
Imoto K, Greenough WT, Rhyu IJ: Developmental characteristics of
dendritic spines in the dentate gyrus of Fmr1 knockout mice. Brain Res
2010, 1355:221–227.
42. Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X: The therapeutic
effect of memantine through the stimulation of synapse formation and
dendritic spine maturation in autism and fragile X syndrome. PLoS One
2012, 7:e36981.
43. Zhou X, Song M, Chen D, Wei L, Yu SP: Potential role of KCNQ/M-channels
in regulating neuronal differentiation in mouse hippocampal and
embryonic stem cell-derived neuronal cultures. Exp Neurol 2011,
229:471–483.
44. Liebau S, Vaida B, Proepper C, Grissmer S, Storch A, Boeckers TM, Dietl P,
Wittekindt OH: Formation of cellular projections in neural progenitor cells
depends on SK3 channel activity. J Neurochem 2007, 101:1338–1350.
45. Boda B, Mendez P, Boury-Jamot B, Magara F, Muller D: Reversal of activity‐
mediated spine dynamics and learning impairment in a mouse model of
Fragile X syndrome. Eur J Neurosci 2014, 39:1130–1137.
46. De Vrij F, Levenga J, Van der Linde HC, Koekkoek SK, De Zeeuw CI,
Nelson DL, Oostra BA, Willemsen R: Rescue of behavioral phenotype and
neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008,
31:127–132.
47. Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS: GSK3 influences social
preference and anxiety-related behaviors during social interaction in a
mouse model of fragile X syndrome and autism. PLoS One 2010, 5:e9706.
48. Sun MK, Hongpaisan J, Lim CS, Alkon DL: Bryostatin-1 restores
hippocampal synapses and spatial learning and memory in adult fragile
x mice. J Pharmacol Exp Ther 2014, 349:393–401.
49. Shi D, Xu S, Waddell J, Scafidi S, Roys S, Gullapalli RP, McKenna MC:
Longitudinal in vivo developmental changes of metabolites in the
hippocampus of Fmr1 knockout mice. J Neurochem 2012, 123:971–981.
50. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME:
A metabolomic and systems biology perspective on the brain of the
fragile X syndrome mouse model. Genome Res 2011, 21:2190–2202.
51. Yuskaitis CJ, Beurel E, Jope RS: Evidence of reactive astrocytes but not
peripheral immune system activation in a mouse model of Fragile X
syndrome. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis 2010,
1802:1006–1012.
52. Brand A, Richter-Landsberg C, Leibfritz D: Multinuclear NMR studies on the
energy metabolism of glial and neuronal cells. Dev Neurosci 1993, 15:289–298.
53. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD: Alzheimer
disease: depiction of increased cerebral myo-inositol with proton MR
spectroscopy. Radiology 1993, 187:433–437.
54. Yang Q, Feng B, Zhang K, Guo Y-y, Liu S-b, Wu Y-m, Li X-q, Zhao M-g:
Excessive astrocyte-derived neurotrophin-3 contributes to the
abnormal neuronal dendritic development in a mouse model of
fragile x syndrome. PLoS Genet 2012, 8:e1003172.
55. Higashimori H, Morel L, Huth J, Lindemann L, Dulla C, Taylor A, Freeman M,
Yang Y: Astroglial FMRP-dependent translational down-regulation of
mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile
X mouse. Hum Mol Genet 2013, 22:2041–2054.
56. Jacobs S, Doering LC: Astrocytes prevent abnormal neuronal
development in the fragile x mouse. J Neurosci 2010, 30:4508–4514.
doi:10.1186/s13023-014-0124-6
Cite this article as: Hébert et al.: Rescue of fragile X syndrome phenotypes
in Fmr1 KO mice by a BKCa channel opener molecule. Orphanet Journal of
Rare Diseases 2014 9:124.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hébert et al. Orphanet Journal of Rare Diseases 2014, 9:124 Page 10 of 10
http://www.ojrd.com/content/9/1/124
